Clinical trials · Pennsylvania
Breast Cancer Female clinical trials in Pennsylvania
We’re tracking 58 recruiting breast cancer female studies with a site in Pennsylvania — including Early Phase 1, Phase 1, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Pennsylvania
- NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial is testing an experimental oral drug called NKT3964 for people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein called CDK2, which some cancers need to grow.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06888388Recruiting
Safety of nipple-sparing mastectomy for women with high-risk genes
This study looks at the long-term safety of a type of breast surgery (nipple-sparing mastectomy) in women who carry certain inherited gene changes (BRCA1, BRCA2, PALB2, TP53, CDH1, or PTEN) that increase their risk of breast cancer. The goal is to understand how safe this surgery is over time for these women.
Philadelphia, PennsylvaniaAges 18–90 - NCT07029399RecruitingPhase 1
Study of NKT5097 for advanced solid tumors
This trial tests an experimental oral drug (NKT5097) for people with advanced solid tumors that have not responded to other treatments. It may also be an option for people with a specific type of breast cancer (HR+/HER2-). The goal is to see if the drug is safe and effective.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT02732171Recruiting
Blood and bone marrow tests to track breast cancer return
This trial checks whether specific “surveillance” markers (measured from blood and bone marrow) can help predict if breast cancer comes back after standard treatments. It may help doctors monitor you more accurately and earlier if recurrence risk is high.
Philadelphia, PennsylvaniaAges 18 years+ - NCT02945579Recruiting
Testing skipping breast surgery or radiation for top responders
This trial studies whether some people with early-stage breast cancer who respond extremely well to hormone/chemo/targeted treatment can safely skip breast surgery and/or radiation. It aims to reduce side effects without increasing cancer risk in carefully selected patients.
Pittsburgh, PennsylvaniaAges 30 years+ - NCT06380751RecruitingPhase 3
New targeted therapy for BRCA/PALB2-mutated HR+ breast cancer
This trial tests a new combination of targeted therapies (saruparib plus camizestrant or hormone therapy) against standard treatments for people with a specific type of advanced breast cancer. It may be a good option if you have a BRCA1, BRCA2, or PALB2 gene mutation and have not yet had treatment for your advanced disease.
Hershey, PennsylvaniaAges 18 years+ - NCT07310420RecruitingPhase 1
Zoladex injection for ovarian suppression in advanced breast cancer
This trial tests a single injection of Zoladex (goserelin) to see how well it suppresses ovarian function in premenopausal women with HR+, HER2- advanced breast cancer. It may be an option if you are still having periods and your cancer has spread or cannot be removed by surgery.
Bethlehem, PennsylvaniaAges 18–55 - NCT05827081RecruitingPhase 3
Ribociclib plus endocrine therapy for early breast cancer
This trial studies whether adding ribociclib to standard hormone (endocrine) therapy lowers the risk of breast cancer coming back in early-stage, hormone-receptor–positive cancer. It mainly looks at safety and how well the treatment controls cancer after surgery and (sometimes) prior hormone treatment.
Drexel Hill, PennsylvaniaAges 18–100 - NCT07478016Recruiting
Studying inflammation and social factors in breast cancer
This study looks at how inflammation and social factors (like stress or support) affect breast cancer patients before they start treatment. You may qualify if you are a woman, newly diagnosed, and have not yet had any cancer treatment.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04468061RecruitingPhase 2
Study chemo drug plus immunotherapy for metastatic triple-negative breast cancer
This trial tests sacituzumab govitecan (an antibody-drug medicine) with or without pembrolizumab (an immune-system therapy) in people with metastatic triple-negative breast cancer. It may help by shrinking tumors and improving immune control, especially for patients with specific tumor marker results.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06757634RecruitingPhase 3
A study of gedatolisib for first-line advanced breast cancer
This trial tests a new targeted therapy called gedatolisib for people with HR-positive, HER2-negative advanced breast cancer who have not yet received treatment for metastatic disease. It aims to see if adding this drug to standard hormone therapy can help control the cancer longer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06774963RecruitingPhase 1
Study of LNCB74 for advanced solid tumors
This trial tests a new drug called LNCB74 for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and effective.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05564377RecruitingPhase 2
Find targeted cancer treatments using genetic testing
This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.
Allentown, PennsylvaniaAges Any age - NCT05625659Recruiting
Breast cancer screening for dense breasts using new X-ray scans
This trial compares two imaging tests—CESM (a contrast-enhanced mammogram) and DBT (3D mammography)—to see which works best for women with dense breast tissue. It may help improve how early breast changes are found in dense breasts.
Philadelphia, PennsylvaniaAges 45–74 - NCT06103864RecruitingPhase 3
Study of Dato-DXd with or without durvalumab for advanced triple-negative breast cancer
This trial is testing whether a new drug combination (Dato-DXd with or without durvalumab) works better than standard chemotherapy plus pembrolizumab for people with a certain type of advanced triple-negative breast cancer that has a protein called PD-L1. The study aims to find a more effective treatment option for this specific group.
York, PennsylvaniaAges 18 years+ - NCT07319195RecruitingEarly Phase 1
Study of a new drug injected into tumors for breast cancer
This trial tests a drug called mitazalimab injected directly into the tumor for patients with early-stage or recurrent breast cancer who are scheduled for surgery. The goal is to see if this approach can help the immune system fight the cancer before surgery.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06695845RecruitingPhase 2
Study of zanidatamab for HER2-positive solid tumors
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
Horsham, PennsylvaniaAges 18 years+ - NCT06435429RecruitingPhase 3
Zanidatamab vs trastuzumab for HER2+ breast cancer
This study compares a new drug called zanidatamab against trastuzumab (Herceptin), both given with a chemotherapy of your doctor's choice. It is for people with HER2-positive breast cancer that has spread and who have already tried T-DXd treatment.
Philadelphia, PennsylvaniaAges 18 years+ - NCT03804944RecruitingPhase 2
Vaccine trial for hormone-positive breast cancer
This Phase 2 study tests an individualized vaccine made from your tumor information to help your immune system fight hormone-positive breast cancer. You may be able to participate if you meet specific hormone-receptor, health, and treatment-timing requirements.
Pittsburgh, PennsylvaniaAges 18–90 - NCT07214532Recruiting
Guiding CDK4/6 inhibitor use by a blood test in breast cancer
This trial is for women and men with early-stage, hormone-positive, HER2-negative breast cancer. It uses a blood test (Signatera) to detect tiny amounts of cancer DNA and only starts a CDK4/6 inhibitor (ribociclib or abemaciclib) if the test shows cancer DNA is present.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT04862663RecruitingPhase 3
Capivasertib plus hormone therapy for HR+ breast cancer after progression
This Phase 3 trial studies capivasertib (a targeted pill) plus fulvestrant (a hormone injection) together with a CDK4/6 inhibitor to treat HR+ / HER2- advanced breast cancer that has returned or grown despite earlier hormone therapy. It may help by blocking growth signals linked to cancer cell survival.
Philadelphia, PennsylvaniaAges 18–99 - NCT07038785Recruiting
Can trained dogs find breast cancer from breath?
This trial will see if specially trained dogs can identify breast cancer by smelling breath samples. You would give a breath sample and the dogs will be tested on how well they can detect cancer from it.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05645536Enrolling by invitationPhase 3
Safety follow-up for hormone-positive, HER2-negative breast cancer
This trial studies the safety of continuing endocrine therapy with ovarian suppression (for women) after you finish the earlier OVELIA study. It may help doctors confirm that the treatment remains safe for longer-term use.
Wynnewood, PennsylvaniaAges 18–51 - NCT05879926RecruitingPhase 3
Testing chemo after hormone therapy in premenopausal early breast cancer
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
Allentown, PennsylvaniaAges 18–60
Breast Cancer Female trials by city in Pennsylvania
Where these studies are running in Pennsylvania
Institutions with a site for the recruiting breast cancer female studies listed above.
- University of Pennsylvania · 7 studies
- Thomas Jefferson University Hospital · 6 studies
- UPMC Hillman Cancer Center · 4 studies
- Fox Chase Cancer Center · 3 studies
- Lankenau Medical Center · 3 studies
- Research Site · 3 studies
- Allegheny General Hospital · 2 studies
- Asplundh Cancer Pavilion · 2 studies
What taking part in a breast cancer female study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Breast Cancer Female trials in other states
Common questions
- Are there breast cancer female clinical trials in Pennsylvania?
- Yes. We're currently tracking 58 recruiting breast cancer female studies with a site in Pennsylvania, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a breast cancer female study in Pennsylvania?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Pennsylvania to take part?
- Not necessarily. These studies have a site in Pennsylvania, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a breast cancer female trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New breast cancer female studies open in Pennsylvania regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.